Spyros Papapetropoulos, MD, PhD is a Neurologist, biopharmaceutical CEO, board leader, and company builder with more than two decades of experience creating, financing, transforming, and scaling CNS-focused biotechnology companies. He has held senior executive and board roles across public and private biotech and global pharmaceutical organizations, with leadership experience spanning corporate strategy, R&D execution, capital formation, business development, strategic partnerships, IPOs, and M&A. Dr. Papapetropoulos has led organizations and programs across neurodegeneration, neuropsychiatry, rare disease, and movement disorders, contributing to more than 20 INDs, multiple NDA/sBLA submissions, global product launches, major financings, and strategic transactions. His career includes leadership roles at Neuphoria, Vigil Neuroscience, Cavion, Acadia, Teva, Pfizer, Biogen, and multiple public-company boards. He is recognized for building high-performing teams, translating differentiated science into investable development strategies, and positioning companies for partnership, financing, and long-term value creation.